Drug
BEBT-908 for Injection
BEBT-908 for Injection is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
2
67%
Ph phase_2
1
33%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Other(2)
Detailed Status
unknown2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (66.7%)
Phase 21 (33.3%)
Trials by Status
completed133%
unknown267%
Recent Activity
0 active trials
Showing 3 of 3
unknownphase_1
Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06164327
completedphase_1
Study of BEBT-908 in Subjects With Advanced Hematological Tumors
NCT06082596
unknownphase_2
Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects
NCT06074107
Clinical Trials (3)
Showing 3 of 3 trials
NCT06164327Phase 1
Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06082596Phase 1
Study of BEBT-908 in Subjects With Advanced Hematological Tumors
NCT06074107Phase 2
Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3